GATC Health Slashes Drug Development Time from 10 to 2 Years with Multinomics Advanced Technology
Jakarta, August 26, 2025 — Typically, pharmaceutical companies require 10 to 15 years to develop a new drug, a process that incurs enormous costs reaching billions to trillions of rupiah. However, emerging health challenges demand faster availability of effective treatments. Addressing this critical need, GATC Health, a biotechnology company headquartered in California, USA, has introduced a groundbreaking innovation that drastically shortens drug development timelines.
Using its proprietary Multinomics Advanced Technology™ (MAT), GATC Health can now accelerate the development of new drugs from a decade to just two years. MAT integrates large-scale human biology data with advanced scientific methodologies, powered by artificial intelligence (AI) simulation platforms. This fusion enables precise prediction of a drug candidate’s success or failure early in the development process.
Validated through double-blind clinical studies conducted by the University of California, Irvine, MAT has demonstrated an impressive 86% accuracy in diagnosing diseases, predicting the efficacy of potential drug candidates, and assessing their safety, including side effect risks for patients. Furthermore, the technology can forecast with 91% accuracy which drug candidates are likely to fail or require further refinement to meet desired therapeutic goals.
This innovative capability earned GATC Health the exclusive AI platform role in a clinical trial financing program supported by Blackstone and London-based Lloyd’s of London. This partnership has unlocked access to over USD 100 billion in potential funding to accelerate healthcare innovation worldwide. One major breakthrough is the creation of a novel “clinical trial insurance” product—an industry first—that insures pharmaceutical companies during clinical trials, mitigating financial risks in drug development.
Dr. Rahul Gupta, president of GATC Health, leads these cutting-edge advancements. Before joining GATC, Dr. Gupta served as the White House Drug Czar and Director of the Office of National Drug Control Policy (ONDCP) under President Joe Biden’s administration.
Expanding its impact, GATC Health is offering licenses for this innovative MAT technology to countries in Southeast Asia, including Indonesia. This transfer aims to lower development costs and expedite new treatments for critical diseases such as diabetes, tuberculosis, cancer, lupus, and Alzheimer’s disease, ultimately improving patient outcomes and quality of life in the region.
With the adoption of GATC’s Multinomics Advanced Technology, the future of drug development looks promisingly faster, smarter, and more cost-effective—heralding a new era in global healthcare innovation.
Reported by Tresnawati for Suara Merdeka Jakarta.
